21:21 , Feb 3, 2017 |  BC Week In Review  |  Company News

Sanofi sales and marketing update

Sanofi’s Sanofi Pasteur vaccine division launched Quadracel vaccine in the U.S. to prevent diphtheria, tetanus, pertussis and poliomyelitis in children ages 4-6. The CDC recommends children ages 4-6 receive both their fifth dose of the...
07:00 , Apr 6, 2015 |  BC Week In Review  |  Clinical News

Quadracel regulatory update

FDA approved a BLA from Sanofi for Quadracel vaccine to prevent diphtheria, tetanus, pertussis and poliomyelitis in children ages 4-6. The CDC recommends children ages 4-6 receive both their fifth dose of the diphtheria,...
08:00 , Feb 9, 2015 |  BC Week In Review  |  Clinical News

Ai Bi Wei regulatory update

China approved Ai Bi Wei vaccine from the Institute of Medical Biology of the Chinese Academy of Sciences to prevent polio in newborns. Ai Bi Wei is the world’s first inactivated Sabin strain polio vaccine....
01:54 , May 10, 2014 |  BC Extra  |  Clinical News

Pfizer reports Phase II data for meningitis B vax

Pfizer Inc. (NYSE:PFE) reported data from a pair of Phase II trials evaluating rLP2086 to vaccinate adolescents against meningococcal disease caused by Neisseria meningitidis serogroup B. One month after the last dose in the...
07:00 , Oct 27, 2008 |  BC Week In Review  |  Company News

GlaxoSmithKline sales and marketing update

GlaxoSmithKline announced in its 3Q08 earnings that it launched its Kinrix DTaP-IPV vaccine to prevent diphtheria, tetanus, acellular pertussis and polio in children 4-6 years old. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.   Business: Infectious...
07:00 , Jun 30, 2008 |  BC Week In Review  |  Company News

GlaxoSmithKline, sanofi-aventis, Centers for Disease Control and Prevention infectious news

The CDC Advisory Committee on Immunization Practices (ACIP) voted to add sanofi-aventis' Pentacel combination vaccine, GlaxoSmithKline's Rotarix oral attenuated rotavirus vaccine and GlaxoSmithKline's Kinrix DTaP-IPV vaccine to the federal government's Vaccines for...
07:00 , Jul 30, 2007 |  BC Week In Review  |  Clinical News

Kinrix regulatory update

GSK submitted a marketing application to FDA for Kinrix, a DTaP-IPV vaccine, to vaccinate against diptheria, tetanus, acellular pertusis and polio in children 4 to 6 years of age. GlaxoSmithKline plc (LSE:GSK; GSK), London, U.K....
07:00 , Jun 30, 1997 |  BC Week In Review  |  Clinical News

Certiva DTaP-IPV vaccine (diphtheria, tetanus, acellular pertussis, and polio): Update

North American Vaccine Inc. (NVX), Beltsville, Md.   Product: Certiva DTaP-IPV vaccine (diphtheria, tetanus, acellular pertussis, and polio)   Indication: Childhood immunization   Status: NVX filed an IND to test the safety and immunogenicity of the DTaP vaccine...
08:00 , Nov 4, 1996 |  BioCentury  |  Strategy

Lining up the acellular pertussis competition

WASHINGTON - Beyond the immediate spotlight put on North American Vaccine Inc.'s Certiva acellular pertussis vaccine, last week's meeting of the FDA's Vaccines and Related Biological Products Advisory Committee focused attention on the coming competition...
07:00 , Oct 7, 1996 |  BC Week In Review  |  Clinical News

North American Vaccine regulatory update

Denmark approved a combined DTaP-IPV vaccine to prevent diphtheria, tetanus, pertussis (whooping cough) and polio for primary and booster doses for infants and children. The vaccine, which was developed jointly by NVX and Statens Seruminstitut...